Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study.

Chunyan LanHuaiwu LuLin ZhouKunlun LiaoJunxiu LiuZhiwen XieHaixi LiangGuorong ZouTing YangQin XuXin Huang

Published in: Cancer communications (London, England) (2024)

Long-term survival follow-up data demonstrated that camrelizumab plus apatinib has robust, sustained, and durable efficacy in patients with advanced cervical cancer who progress after first-line platinum-based chemotherapy. No new safety signals were noted with long-term treatment.

Keyphrases

phase ii
clinical trial
open label
electronic health record
locally advanced
squamous cell carcinoma
phase iii
randomized controlled trial
big data
type diabetes
data analysis
study protocol
newly diagnosed